glp 1 agonist kidney disease GLP-1 agonists in the treatment of chronic in type 2 diabetes and obesity Kidney Outcomes With Glucagon-Like Peptide-1

Obesity and type 2 diabetes remain critical global health challenges, with rising prevalence demanding innovative treatment approaches

Methods We obtained the data from PubMed, Scopus, Embase, and Web of Science for all eligible studies, including clinical trials (RCT) and cohorts comparing GLP-1 RAs to placebo or other hypoglycemic agents in patients with HFpEF published until December 31st, 2024

Set Point Medical Weight Loss Clinic Offers FDA Approved Semaglutide GLP-1 For Supporting Chronic Weight Loss Management.

No side effects like the nausea or headache

drugs like Ozempic).

Reddy's Laboratories Limited for manufacturing...